NBIX Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Neurocrine Biosciences Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 143.03 USD 3.99%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast NBIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NBIX is 155 USD with a low forecast of 107.06 USD and a high forecast of 210 USD.

NBIX Lowest Forecast

Wall Street Target

NBIX Average Forecast

Wall Street Target

NBIX Highest Forecast

Wall Street Target

25% Downside

8% Upside

47% Upside

The latest public price target was made on Apr 23, 2024 by Mohit Bansal from Wells Fargo , who expects NBIX stock to rise by 19% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Mohit Bansal Wells Fargo	170 USD Upside 19%	1 week ago Apr 23, 2024	Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club' StreetInsider
Jay Olson Oppenheimer	200 USD Upside 40%	1 month ago Mar 12, 2024	Neurocrine Bio. (NBIX) PT Raised to $200 at Oppenheimer, 'increasingly optimistic for NBIX's M4 agonist ahead of Ph2 topline results' StreetInsider
Unknown Analyst Morgan Stanley	130 USD Downside 9%	1 year ago Feb 3, 2023	Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130 Benzinga

Price Target	170 USD
Upside/Downside	19%

Price Target	200 USD
Upside/Downside	40%

Price Target	130 USD
Upside/Downside	9%

Exscientia PLC

72% Upside

Affimed NV

331% Upside

Beijing Leadman Biochemistry Co Ltd

264% Upside

Organogenesis Holdings Inc

96% Upside

Exscientia PLC

72% Upside

Affimed NV

331% Upside

Beijing Leadman Biochemistry Co Ltd

264% Upside

Organogenesis Holdings Inc

96% Upside

Lepu Biopharma Co Ltd

32% Downside

Incyte Corp

45% Upside

Zealand Pharma A/S

22% Upside

Biocytogen Pharmaceuticals Beijing Co Ltd

172% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 77%. The projected CAGR for the next 3 years is 16%.

77%

16%

-2%

What are analyst estimates?

Operating Income
Forecast

The compound annual growth rate of Neurocrine Biosciences Inc's operating income for the next 3 years is 42%.

N/A

42%

0%

What are analyst estimates?

Net Income
Forecast

The compound annual growth rate of Neurocrine Biosciences Inc's net income for the next 3 years is 52%.

N/A

52%

-17%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for NBIX is 155 USD with a low forecast of 107.06 USD and a high forecast of 210 USD.

For the last 8 years the compound annual growth rate for Neurocrine Biosciences Inc's revenue is 77%. The projected CAGR for the next 3 years is 16%.

The compound annual growth rate of Neurocrine Biosciences Inc's operating income for the next 3 years is 42%.

The compound annual growth rate of Neurocrine Biosciences Inc's net income for the next 3 years is 52%.

Join more than 133,300+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.